Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases

Journal of Medical Virology

Volumn 83, Issue 2, 2011, Pages 311-316

  Haque, Tanzina ^a   Chaggar, Turren ^a   Schafers, Jenna ^b   Atkinson, Claire ^a   McAulay, Karen A ^b   Crawford, Dorothy H ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acute IM; EBV; PTLD; Serum marker; Soluble CD30

Indexed keywords

CD30 ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; VIRAL LOAD;

HUMAN HERPESVIRUS 4;

EID: 78650376729     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21953     Document Type: Article

References (26)

1. Adams H, Campidelli C, Dirnhofer S, Pileri SA, Tzankov A. 2009. Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 13: 1137-1145.
2. Ciferska H, Horak P, Hermanova Z, Ordeltova M, Zadrazil J, Tichy T, Scudla V. 2007. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 26: 723-728.
3. Emery VC, Einsele H, Atabani S, Haque T. 2010. Immunotherapy and vaccination after transplant: The present, the future. Infect Dis Clin North Am 24: 515-529.
4. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. 1995. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85: 1-14.
5. Gregory CD, Edwards CF, Milner A, Wiels J, Lipinski M, Rowe M, Tursz T, Rickinson AB. 1988. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int J Cancer 42: 213-220.
6. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. 1994. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 2045-2056.
7. Hansen HP, Recke A, Reineke U, Von TB, Borchmann P, Von Strandmann EP, Lange H, Lemke H, Engert A. 2004. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 18: 893-895.
8. Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H. 2007. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 83: 706-711.
9. Hopwood PA, Brooks L, Parratt R, Hunt BJ, Bokhari M, Thomas JA, Yacoub M, Crawford DH. 2002. Persistent Epstein-Barr virus infection: Unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 74: 194-202.
10. Horie R, Watanabe T. 1998. CD30: Expression and function in health and disease. Semin Immunol 10: 457-470.
11. Jabs WJ, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, Kirchner H, Wagner HJ. 2001. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 39: 564-569.
12. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. 1989. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19: 157-162.
13. Lok C, Viseux V, Denoeux JP, Bagot M. 2005. Post-transplant cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 56: 137-145.
14. McAulay KA, Haque T, Crawford DH. 2009. Tumour necrosis factor gene polymorphism: A predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 101: 1019-1027.
15. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundström C, Enblad G, Nilsson G. 2001. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 114: 616-623.
16. Niederman JC, Evans AS, Subrahmanyan L, McCollum RW. 1970. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med 282: 361-365.
17. Oflazoglu E, Grewal IS, Gerber H. 2009. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 647: 174-185.
18. Pellegrini P, Berghella AM, Contasta I, Adorno D. 2003. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 12: 49-61.
19. Romagnani S, Del PG, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. 1995. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 57: 726-730.
20. Sadeghi M, Susal C, Daniel V, Naujokat C, Zimmermann R, Huth-Kuhne A, Opelz G. 2007. Short communication: Decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses 23: 886-890.
21. Schwend M, Tiemann M, Kreipe HH, Schwend M, Tiemann M, Kreipe HH, Parwaresch MR, Kraatz EG, Herrmann G, Spielmann RP, Barth J. 1994. Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation. Eur Resp J 7: 612-616.
22. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. 2006. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 81: 1216-1219.
23. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. 2008. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 45: 3133-3141.
24. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73: 1349-1360.
25. Vinante F, Morosato L, Siviero F, Nadali G, Rigo A, Veneri D, Sabata D, Vincenzi C, Chilosi M, Semenzato G, Pizzolo G. 1994. Soluble forms of p55-IL-2R alpha, CD8, and CD30 molecules as markers of lymphoid cell activation in infectious mononucleosis. Haematologica 79: 413-419.
26. Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G. 2006. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 77: 387-394.